João Eurico Fonseca, 15 Ilaria Galetti, 24 Eric Hachulla, 25 Ulf Mueller-Ladner, 26 Matthias Schneider, 27 Vanessa Smith, 28 Maurizio Cutolo, 17 Marta Mosca, 18, 29 Nathalie Costedoat-Chalumeau Within the ERN ReCONNET, the SLE core set network is composed of the members of the network involved in SLE, of FT and NC-C (the official SLE Disease Coordinators, junior and senior) and of two methodologists of the ERN ReCONNET.
The SLE core set network is addressed to focus on the management of all forms of SLE disease manifestations, including rare and complex conditions.
One of the first core set network targets was to identify the currently available CPGs pertaining to SLE, in order to identify potential unmet needs, which should be further focused on. A literature search included all the papers published until July 2017. In order to implement the list of guidelines provided by MEDLINE and Embase search, the group also performed a hand search.
Methodology of CPGs identification
All references included in the final list (systematic search+hand search) identified during the systematic literature search were screened for eligibility by two evaluators, the Disease Coordinators (NC-C and FT) of the ERN ReCONNET for SLE, based on title and abstract assessment. We addressed the following question: does this paper describe CPG? Manuscripts scored as such by at least one of the two evaluators were included in the next step.
The two evaluators then assessed all selected references with the full article in order to confirm that they were CPGs. In case of no agreement, a further round of discussion involving a third evaluator (LA) was performed, in order to reach consensus.
A discussion group was set up to confirm inclusion and evaluation of the selected CPGs. The topics covered by each guideline were systematically evaluated by one member of the group (FF) in order to guide the discussion group during the identification of the unmet needs. Physician's unmet needs were then defined by the group, each participant giving his thoughts regarding what is not currently addressed by the current guidelines.
Finally, the patient's unmet needs paragraph intends to highlight the unmet needs of the European lupus community. The content of this paragraph has been realised by the ERN ReCONNET European Patient Advocacy Group that carefully collected the voices and the points of view of the whole European community of the disease they represent by means of meetings and web conferences.
RESULTS

State of the art on CPGs Identification of existing CpGs
The systematic literature search yielded a total of 2272 citations. Title and abstract evaluation identified 52 papers suitable for full-text review. After full-text review, 21 original guidelines were identified 2-23 (figure 1. Of note, Saavedra et al published one guideline, which is divided into two parts with two different references, but this guideline was counted as one in the systematic search. 15 16 Two articles were included by hand search, 24 25 leading to a total of 23 CPGs. The general characteristics of the 23 CPGs are summarised in table 1. Twenty-one were in English Five CPGs involved patient representatives and one involved a patient panel. Fifteen CPGs were dedicated to SLE, while eight covered a broader spectrum of rheumatic diseases (including SLE). Seventeen targeted all patients (juvenile and adult), four papers specifically targeted juvenile SLE and two female SLE. Five CPGs addressed general management of SLE, five addressed prevention or treatment of infections (three specifically focusing on vaccination), four focused on a specific SLE organ involvement (three on renal disease and one on neuropsychiatric disease) two addressed immunologic laboratory testing, while others focused on pregnancy and family planning (n=2), cardiovascular risk management (n=2), cancer (n=1), orthopaedic perioperative management (n=1) or fatigue (n=1).
UNMET NEEDS Clinicians' unmet needs
This review provides an overview of currently available CPGs for SLE. Yet, there are several areas that are not (yet) covered by guidelines.
The following items were considered as correctly covered: (1) global management of SLE, 5 10 14 20 22 including a treatto-target strategy 22 ; (2) autoantibodies testing 4 19 ; (3) Lupus Lupus Lupus RMD Open RMD Open RMD Open ; and (9) Perioperative management for hip and knee surgery. 9 By contrast, several clinician's unmet needs were identified: (1) optimal management of serositis, gastrointestinal involvement, interstitial lung disease, retinal vasculitis, limited cutaneous disease, headaches and/or severe lymphopaenia that are not covered by the current available CPGs. (2) Evaluation and management of non-adherence to treatment is a crucial missing point which is only addressed by one available CPG.
10 (3) Optimal duration of immunosuppression, which is only partly addressed in some guidelines. (4) Patient's input on CPGs is missing. Only one CPG proposed patient assessment as a recommendation, which consisted in an evaluation of her/his quality of life by using a visual analogue scale.
14 (5) Except one CPG on LN, 11 none of the available CPGs addressed the important question of ethnicity and its possible impact on disease severity. (6) No definition of photosensitivity and vasculitis is provided in current CPGs. (7) No mention of non-health related prognostic determinants, such as patients' socioeconomic status.
Patients' unmet needs
The first unmet need identified by patients deals with delay and uncertainty in diagnosis until confirmation by a specialist. This adds to the psychological burden of the disease, which might be aggravated if treatment is delayed. The need for new treatment options, less reliant on steroids and associated with fewer side effects, is a high priority for patients. They advocate a more holistic disease management, going beyond specific symptoms or an 'organ by organ' management, to include a global treatment plan, coordinated by one physician, in casu a lupus expert, who treat them as a 'full person' and takes care, besides the clinical aspects, of the psychological issues. In our working group meetings, lupus patients defined treatment as "any product or activity aiming at improving quality of life", clearly pinpointing the importance of a holistic approach. Patients are looking for scientifically validated patient focused guidelines on lifestyle issues. Research should be conducted jointly by HCPs and patient organisations to identify behaviours or actions that can help patients take day-to-day ownership of their treatment, understanding what to do, or not to do, based on hard data. Even if remission of SLE disease activity has been achieved, many patients still face pain and fatigue. Understanding the drivers would allow building treatment guidelines for those conditions, which is critical to avoid that people facing these symptoms are pushed prematurely out of the labour market. Finally, while a huge amount of information is available to patients on the web, this information is of very low quality, often counterproductive and anxiety generating. There is a need for high-quality therapeutic patient education and for an efficacious way to fight fake news that spread over the internet, for example, by quality certified information, or diffusion of ERN-endorsed recommendations via social media posts.
CONCLUSIONS
Here we proposed an overview of the current available CPGs on SLE. Many unmet needs have been identified. Soon after we performed the systematic research, two clinical guidelines have been published. 26 27 Gordon et al published the British guideline on SLE, 26 which proposed recommendations for some of these unmet needs, such as patient reported outcomes (Short Form (SF)-36 and Lupus QoL indices) and for immunosuppression duration. Pons-Estel et al 27 published another guideline with a focus on socioeconomic and ethnic-namely in Latin Americans-aspects. Yet, many areas remain uncovered, and efforts are still needed to improve and standardise our daily practice. 
